A couple of fascinating videos about a manufacturer’s equipment for locating critical nerves when performing nerve-sparing robotic RP: http://www.propepsurgical.com/patient-benefits.html Gives you an idea why nerve-sparing is so difficult, and not usually 100%.
Patients enduring the excruciating pain of cancer that has spread to the bones are often given multiple doses of radiation. There is strong evidence, however, that one dose controls pain as effectively as 10 or more. In addition, one treatment is cheaper and far more convenient for patients who already have plenty on their minds. Read the Article.
September 2013 Scotiabank Awareness Night “Prostate Cancer – identifying men at high risk before it’s too late” Dr. Danny Vesprini, MD, MSc, BSc, FRCPC Assistant Professor Department of Radiation Oncology, University of Toronto Staff Radiation Oncologist, Sunnybrook Odette Cancer Centre Dr. Vesprini discusses the current and upcoming strategies for screening and ultimately treating men who are at increased risk of developing aggressive prostate cancer, including men with a strong family history, men with a known genetic trait that causes aggressive disease, and men of Western African/Caribbean descent. CLICK ON THE ARROW TO START THE VIDEO Click here for Complete Video Introduction by …
If you or someone close to you has lived with prostate cancer, you’ve probably come across dozens of emerging treatments in your hours of Googling. One such treatment, focal therapy, has been dubbed the “new pain-free treatment for prostate cancer”. But don’t hold your breath; it’s still in its experimental phases. This is a warning that focal therapy is still experimental and should be considered only in a clinical trial setting. Read the article.
Prostate Cancer Foundation Announces New Urine Test for Prostate Cancer Available; Unlike PSA Test, is Ultra Specific for Prostate Cancer A new urine test for prostate cancer that measures minute fragments of RNA is now commercially available to men nationwide through the University of Michigan MLabs. The new test—Mi-Prostate Score (MiPS)—improves the utility of the PSA blood test, increases physicians’ ability to pick out high-risk prostate tumors from low-risk tumors in patients, and may help tens of thousands of men avoid unnecessary biopsies. Read the article.